BACKGROUND: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is characterized by severe systemic autoimmunity caused by mutations in the forkhead box protein 3 (FOXP3) gene. Hematopoietic cell transplantation is currently the only viable option for long-term survival, but patients are frequently very ill and may not tolerate traditional myeloablative conditioning regimens. OBJECTIVE: Here we present the outcome of hematopoietic cell transplantation using a low-intensity, nonmyeloablative conditioning regimen in 2 patients with IPEX syndrome and significant pretransplant risk factors. METHODS: Two high-risk patients with IPEX syndrome received HLA-matched related bone marrow or unrelated peripheral blood stem cell grafts following conditioning with 90 mg/m(2) fludarabine and 4 Gy total body irradiation. Postgrafting immunosuppression consisted of mycophenolate mofetil and cyclosporine. Immune reconstitution and immune function was evaluated by measurement of donor chimerism, regulatory T-cell numbers, absolute lymphocyte subsets, and T-cell proliferation assays. RESULTS: Both patients experienced minimal conditioning toxicity and successfully engrafted after hematopoietic cell transplantation. With a follow-up of 4 and 1 years, respectively, patients 1 and 2 have full immune function and normal FOXP3 protein expression. CONCLUSION: A low-intensity, nonmyeloablative conditioning regimen can establish stable engraftment and correct the life-threatening immune deficiency and enteropathy of IPEX syndrome despite the presence of comorbidities that preclude conventional hematopoietic cell transplantation.
BACKGROUND:Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is characterized by severe systemic autoimmunity caused by mutations in the forkhead box protein 3 (FOXP3) gene. Hematopoietic cell transplantation is currently the only viable option for long-term survival, but patients are frequently very ill and may not tolerate traditional myeloablative conditioning regimens. OBJECTIVE: Here we present the outcome of hematopoietic cell transplantation using a low-intensity, nonmyeloablative conditioning regimen in 2 patients with IPEX syndrome and significant pretransplant risk factors. METHODS: Two high-risk patients with IPEX syndrome received HLA-matched related bone marrow or unrelated peripheral blood stem cell grafts following conditioning with 90 mg/m(2) fludarabine and 4 Gy total body irradiation. Postgrafting immunosuppression consisted of mycophenolate mofetil and cyclosporine. Immune reconstitution and immune function was evaluated by measurement of donor chimerism, regulatory T-cell numbers, absolute lymphocyte subsets, and T-cell proliferation assays. RESULTS: Both patients experienced minimal conditioning toxicity and successfully engrafted after hematopoietic cell transplantation. With a follow-up of 4 and 1 years, respectively, patients 1 and 2 have full immune function and normal FOXP3 protein expression. CONCLUSION: A low-intensity, nonmyeloablative conditioning regimen can establish stable engraftment and correct the life-threatening immune deficiency and enteropathy of IPEX syndrome despite the presence of comorbidities that preclude conventional hematopoietic cell transplantation.
Authors: K M Sullivan; E Agura; C Anasetti; F Appelbaum; C Badger; S Bearman; K Erickson; M Flowers; J Hansen; T Loughran Journal: Semin Hematol Date: 1991-07 Impact factor: 3.851
Authors: Marco Mielcarek; Paul J Martin; Wendy Leisenring; Mary E D Flowers; David G Maloney; Brenda M Sandmaier; Michael B Maris; Rainer Storb Journal: Blood Date: 2003-03-27 Impact factor: 22.113
Authors: I Kobayashi; R Shiari; M Yamada; N Kawamura; M Okano; A Yara; A Iguchi; N Ishikawa; T Ariga; Y Sakiyama; H D Ochs; K Kobayashi Journal: J Med Genet Date: 2001-12 Impact factor: 6.318
Authors: J L Goodman; D J Winston; R A Greenfield; P H Chandrasekar; B Fox; H Kaizer; R K Shadduck; T C Shea; P Stiff; D J Friedman Journal: N Engl J Med Date: 1992-03-26 Impact factor: 91.245
Authors: D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas Journal: Bone Marrow Transplant Date: 1995-06 Impact factor: 5.483
Authors: Dietger Niederwieser; Michael Maris; Judith A Shizuru; Effie Petersdorf; Ute Hegenbart; Brenda M Sandmaier; David G Maloney; Barry Storer; Thoralf Lange; Thomas Chauncey; Michael Deininger; Wolfram Pönisch; Claudio Anasetti; Ann Woolfrey; Marie-Terese Little; Karl G Blume; Peter A McSweeney; Rainer F Storb Journal: Blood Date: 2002-10-03 Impact factor: 22.113
Authors: E Mazzolari; C Forino; M Fontana; C D'Ippolito; A Lanfranchi; E Gambineri; H Ochs; R Badolato; L D Notarangelo Journal: Bone Marrow Transplant Date: 2005-05 Impact factor: 5.483
Authors: Z Nademi; M Slatter; E Gambineri; S C Mannurita; D Barge; S Hodges; S Bunn; J Thomas; B Haugk; S Hambleton; T Flood; A Cant; M Abinun; A Gennery Journal: Bone Marrow Transplant Date: 2013-11-25 Impact factor: 5.483
Authors: Rolla F Abu-Arja; Leah R Chernin; Ghada Abusin; Jeffery Auletta; Linda Cabral; Rachel Egler; Hans D Ochs; Troy R Torgerson; Jesus Lopez-Guisa; Robert W Hostoffer; Haig Tcheurekdjian; Kenneth R Cooke Journal: Pediatr Blood Cancer Date: 2015-04-20 Impact factor: 3.167
Authors: Jolan E Walter; Jocelyn R Farmer; Zsofia Foldvari; Troy R Torgerson; Megan A Cooper Journal: J Allergy Clin Immunol Pract Date: 2016 Nov - Dec
Authors: Lauri M Burroughs; Eneida R Nemecek; Troy R Torgerson; Barry E Storer; Julie-An Talano; Jennifer Domm; Roger H Giller; Akiko Shimamura; Colleen Delaney; Suzanne Skoda-Smith; Monica S Thakar; K Scott Baker; David J Rawlings; Janet A Englund; Mary E D Flowers; H Joachim Deeg; Rainer Storb; Ann E Woolfrey Journal: Biol Blood Marrow Transplant Date: 2014-09-06 Impact factor: 5.742